Allogene Overland Biopharm, a joint venture between Overland Pharmaceuticals and Allogene Therapeutics, Inc. (NASDAQ: ALLO), has announced the completion of its state-of-the-art AlloCAR T manufacturing facility in Shanghai, China. This marks a significant milestone in the company’s efforts to expand its cell therapy production capabilities.
State-of-the-Art GMP Facility
The new 68,000 square foot GMP facility in Shanghai features a flexible modular design, making it suitable for all types of cell therapy production. This scalable approach allows for the simultaneous manufacturing of several AlloCAR T products, addressing the unmet needs of patients with cancer in Asia. The facility is designed to support the growing demand for advanced cell therapies and accelerate the development of next-generation AlloCAR T treatments.
Pipeline and Target Candidates
Allogene Overland Biopharm’s pipeline is focused on the development, manufacturing, and commercialization of specific Allogene candidates targeting BCMA, CD70, FLT3, and DLL3 in the licensed territories. The completion of the Shanghai facility underscores the company’s commitment to bringing innovative cell therapies to patients in need across Asia.-Fineline Info & Tech
